Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia
Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia
复制标题
DOI：
10.1185/03007990903471940
复制
发表时间：
2010-02-01
影响因子：
2.3
通讯作者：
Hegazy, Ahmed
中科院分区：
文献类型：
--
作者：
Halawa, Mohamed Reda;Karawagh, Abdullah;Hegazy, Ahmed
目的：确定疼痛性糖尿病周围神经病变的成人糖尿病患者（1型和2型）参加门诊在沙特阿拉伯的患病率，并确定这些patients.Research设计和方法的人口统计学资料和药物管理：符合条件的患者从100个门诊治疗糖尿病患者在沙特阿拉伯完成了流行病学调查问卷，以获得人口统计学信息和用药史。在此之后，使用经验证的DN 4疼痛问卷来识别疼痛性糖尿病周围神经病变的存在（评分>= 4）。根据DN 4疼痛问卷调查，发现疼痛性糖尿病周围神经病变的总患病率为65.3%（n = 678），发现患者的年龄、性别和基础糖尿病的持续时间是发生疼痛性糖尿病周围神经病变的统计学显著因素。吸烟史、体重指数或种族与疼痛性糖尿病周围神经病变之间无统计学显著性差异。在初始评估时，42.3%（n = 440）的患者表示正在接受疼痛治疗。在使用DN 4疼痛问卷进行评估后，处方治疗性疼痛管理的数量增加到三分之二以上（68.7%，n = 714），其中62.3%（n = 579）的患者使用普瑞巴林。结论：在疼痛强度降低的患者中，DN 4尚未与其他测量神经性疼痛的工具直接比较;然而，在这项研究中使用DN 4，发现沙特阿拉伯65.3%的1型和2型糖尿病成人门诊患者患有疼痛性糖尿病周围神经病变;远远高于预期。
Objective:To determine the prevalence of painful diabetic peripheral neuropathy in adult patients with diabetes mellitus (type 1 and 2) attending outpatient clinics in Saudi Arabia and to determine the demographic profile and pharmaceutical management of these patients.Research design and methods:Eligible patients from 100 outpatient clinics treating patients with diabetes mellitus across Saudi Arabia completed an epidemiologic questionnaire to obtain demographic information and medication history. Following this, the validated DN4 pain questionnaire was used to identify the presence of painful diabetic peripheral neuropathy (score of >= 4).Results:A total of 1039 patients were enrolled. Following the DN4 pain questionnaire, an overall prevalence of painful diabetic peripheral neuropathy of 65.3% (n = 678) was found. The age of patients, their sex, and the duration of underlying diabetes were found to be statistically significant factors in the development of painful diabetic peripheral neuropathy. No statistically significant difference was found between smoking history, body mass index, or racial origin and presence of painful diabetic peripheral neuropathy. On initial evaluation, 42.3% (n = 440) stated they were receiving treatment for pain. Following evaluation using the DN4 pain questionnaire, the number prescribed therapeutic pain management increased to more than two thirds (68.7%, n = 714) of which 62.3% (n = 579) were prescribed pregabalin.Conclusions:In patients with reduced pain intensity DN4 has not been directly compared with other tools to measure neuropathic pain; however, using the DN4 in this study 65.3% of adult outpatients with type 1 and 2 diabetes in Saudi Arabia were found to have painful diabetic peripheral neuropathy; far higher than anticipated.